Announcements
Announcement of explanation on the first instance judgment of the civil action between the Company against “Next Magazine”
Parties to the legal matter: Plaintiff: OBI Pharma, Inc. Defendant: Next Digital Ltd., Hong Kong (”Next@Digital”) Name of the court or disposing agency: Taipei District Court, Taiwan Reference/case numbers of …
Announcement of explanation on the Company’s criminal lawsuit against Next Magazine
Parties to the legal matter: OBI Pharma, Inc. Name of the court or disposing agency: Shihlin District Prosecutors Office, Taiwan Reference/case numbers of relevant documents: 2017 Zhen-Zi No. 5025, 5026 …
OBI-833, the cancer therapeutic vaccine, has met the primary safety indicators in Phase I clinical trial for US and Taiwan
Date of occurrence of the event: April 6, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): head office Reciprocal shareholding ratios: …
The board of directors have resolved not to distribute dividends
Date of the board of directors resolution : 9 Mar 2017 (1) Appropriations of earnings in cash dividends to shareholders (NT$ per share): 0 (2) Cash distributed from legal reserve …
Announcement by the Company’s Board of Directors to convene the 2016 Annual General Shareholders’ meeting
Date of the board of directors resolution: Thursday 9 March 2017 Date for convening the shareholders’ meeting: Wednesday 28 June 2017 Location for convening the shareholders’ meeting: 11F., #97, Dunhua …
OBI Pharma’s Board of Directors approves the announcement of the Company’s 2016 individual and consolidated financial statements
Date of the Event: 9 Mar 2017 Company Name: OBI Pharma, Inc Relationship to the Company (enter “Parent” or “Subsidiary”: Parent Reciprocal shareholding ratios: N/A Reason for the Event: The …
Supplemental Information: OBI-822 was approved to enter a Phase III clinical trial by the China Food and Drug Administration (CFDA)
Date of occurrence of the event: January 26, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): Head office Reciprocal shareholding ratios: …
OBI-822 was approved to enter a Phase III clinical trial by the China Food and Drug Administration (CFDA)
Date of occurrence of the event: January 25, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): Head office Reciprocal shareholding ratios: …
OBI Pharma Inc. announces the change of Chief Operating Officer
Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel(CEO, COO, CMO, CSO, etc.),financial officer, accounting officer, research and development officer, or internal audit officer): Chief Operating Officer Date …
Clarification on the news article by Commercial Times
Date of occurrence of the event: January 21, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): N/A Reciprocal shareholding ratios: N/A …